 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- CAT-248 / Catamaran Bio
CAT-248 (engineered NK cells expressing CD70 CAR, IL15, and TGF? DNR) demonstrates in vivo expansion, tumor infiltration, and durable regression of multiple CD70-expressing xenograft tumors (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1312;
Conclusions CAT-248 infiltrates and durably regresses tumor xenografts expressing CD70 at high, medium or low antigen densities. CAT-248 has the potential to be a potent and durably effective allogeneic NK cell therapy for CD70 expressing solid tumors.
- CAT-179 / Catamaran Bio, CAT-248 / Catamaran Bio
Spinner Flask Modelling of Wave-Style Bioreactors Enables Suspension-Phase Cell Culture Process Development of Allogeneic CAR-NK Cell Therapies (Board No. 753) - Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1214;
Two distinct CAR-NK products, CAT-179 and CAT-248, were produced in three different culture systems: 150mL spinner flasks, 1L static cultures and 2L wave-style bioreactors. Use of the model revealed that the optimization of this parameter is critical to maximizing the yield of potent drug products in the CAT-248 process.
- CAT-179 / Catamaran Bio
CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGF? dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice (Section 22; Poster Board #9) - Mar 14, 2023 - Abstract #AACR2023AACR_5071;
Efficacy strongly correlated with the circulating levels of CAT-179, which significantly infiltrated the tumor xenograft. Our pre-clinical results demonstrate the potential of CAT-179 as a novel, durable, and off-the-shelf cell therapy to overcome the challenges associated with solid tumors and provide quantitative insights into pharmacokinetics, pharmacodynamics and anti-tumor activity of engineered NK cells expressing CAR, TGFb DNR and IL-15.
- CAT-248 / Catamaran Bio
CAT-248, an allogeneic CD70-directed CAR-NK cell therapy effectively controls CD70-positive tumor xenografts (Section 22; Poster Board #3) - Mar 14, 2023 - Abstract #AACR2023AACR_5066;
Further, CAT-248 cells demonstrated significant in vivo persistence beyond 4 weeks post-dosing in peripheral blood. Overall, the results demonstrate the potential for CAT-248 as a novel off-the-shelf, cryopreserved, allogeneic NK cell therapy for CD70-positive renal cell carcinoma and other solid tumor malignancies.
- CAT-248 / Catamaran Bio
Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_729;
In functional assays, CD70 knockout CAR-NK cells mediated cytotoxicity against multiple CD70-positive tumor cell lines including AML and RCC both in vitro and in vivo . Conclusions Overall, the results demonstrate the potential for targeting CD70 with CAR-NK cell therapy for the treatment of AML, RCC, and other CD70-positive malignancies while overcoming fratricide issues by engineering with a non-viral transposon delivery system in combination with CRISPR/Cas9 editing.
- CAT-179 / Catamaran Bio
Allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and TGFß dominant negative receptor effectively control HER2+ tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_601;
CAT-179 effectively reduced SKOV-3-luc tumor burden in NSG mice (95% AUC, p<0.0001 for survival). Conclusions CAT-179 is a promising demonstration of the Catamaran CAR-NK platform, as a novel off-the-shelf cell therapy to overcome the challenges associated with solid tumors.
- CAT-179 / Catamaran Bio
Allogeneic Natural Killer cells engineered to express HER2 CAR, Interleukin 15 and TGF beta dominant negative receptor effectively control HER2+ tumors (Section 36) - Mar 9, 2022 - Abstract #AACR2022AACR_2744;
Moreover, CAT-179 administration to NSG mice showed expansion and persistence of the transferred cell product. CAT-179 addresses key hurdles to allogeneic cell therapy for solid tumors and is a promising new therapeutic approach for HER2 expressing breast, gastric and other tumors.
- CAT-248 / Catamaran Bio
Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3274;
2008, Clin Cancer Res. 14(23):7763-7772.